TAS-CC4 Study

ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2614211 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR